[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-volume\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-volume":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100637590","effects-of-creatine-and-heat-exposure-on-exercise-performance-and-body-water-distribution-100637590",false,"NCT07593014","Effects of Creatine and Heat Exposure on Exercise Performance and Body Water Distribution","Creatine Monohydrate Supplementation During Repeated Heat Exposure: Effects on Fluid Balance and Exercise Performance in a Randomized Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Healthy biological males between 18 and 27 years of age\n* Recreationally active males and varsity athletes\n* Able to safely participate in moderate-intensity exercise and heat exposure\n* Willing to maintain habitual diet and physical activity throughout the study\n* Willing to refrain from additional dietary supplementation during study participation\n* Able to attend all required laboratory visits and heat exposure sessions\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of cardiovascular, metabolic, respiratory, renal, neurological, or heat-related illness\n* Contraindications to exercise testing or heat exposure identified during health screening\n* Current musculoskeletal injury limiting exercise participation\n* Current use of creatine supplementation or inability to complete the required washout period\n* Current use of medications or supplements known to affect hydration, thermoregulation, cardiovascular function, or exercise performance\n* Known allergy or intolerance to creatine monohydrate, maltodextrin, or orange juice\n* Inability to comply with study procedures or supplementation protocol\n* Resting tympanic temperature ≥38.0°C prior to a heat exposure session\n* Participation in another research study that may interfere with this protocol",true,"MALE","18 Years","27 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether creatine supplementation changes how the body adapts to repeated exercise in the heat in healthy recreationally active adults and varsity athletes. The study will also examine whether creatine affects fluid balance, blood volume changes and exercise performance.\n\nThe main questions it aims to answer are:\n\nDoes creatine supplementation increase plasma volume and total body water during repeated heat exposure more than placebo? Does creatine supplementation improve exercise performance after heat acclimation more than placebo? Does creatine supplementation influence cardiovascular responses to heat stress?\n\nResearchers will compare a creatine supplementation group to a placebo group to determine whether creatine changes the magnitude of heat acclimation adaptations.\n\nParticipants will:\n\nComplete baseline measurements of body composition, hydration, blood markers, and exercise performance.\n\nConsume either creatine monohydrate or a placebo supplement daily Complete repeated supervised exercise sessions in a controlled heated environment Undergo repeated assessments of body water, temperature, heart rate, and exercise performance throughout the study",[28,29,30,31,32,33,34],"Heat Exposure","Exercise Performance","Hydration","Body Fluid Compartments","Creatine Supplementation","Placebo - Control","Plasma Volume",[36,28,37,38,34,39,31,40,41,42,43],"Creatine Monohydrate","Heat Acclimation","Short Term Heat Acclimation","Fluid Balance","Wingate Test","VO2 Max","Cardiorespiratory Performance","Musculoskeletal Performance","NOT_YET_RECRUITING","2026-05-11",{"date":47,"type":48},"2026-05-18","ACTUAL",{"date":50,"type":22},"2026-07-30",{"date":52,"type":22},"2027-08-30",{"name":54,"class":55},"University of Windsor","OTHER",{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":63,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100602050","phase-4-highcycle-study-acetazolamide-high-altitude-and-plasma-volume-100602050","NCT07118462","HighCycle Study: Acetazolamide, High Altitude and Plasma Volume","HighCycle Study: Effect of Acetazolamide on Plasma Volume During Acute Exposure to High Altitude in Women and Men","Inclusion Criteria:\n\n* Healthy, non-smoking men and women, age 18-44 years, without any disease and need of regular medication (including oral contraceptives).\n* BMI \\>18 kg\u002Fm2 and \\\u003C30 kg\u002Fm2.\n* Born, raised and currently living at altitudes \\\u003C1000 m.\n* Written informed consent.\n* Premenopausal women with an eumenorrheic cycle.\n\nExclusion Criteria:\n\n* Other types of contraceptvies (contraceptives (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others).\n* Pregnancy or nursing\n* Anaemic (haemoglobin concentration \\\u003C10g\u002Fdl).\n* Any altitude trip \\\u003C4 weks before the study.\n* Allergy to acetazolamide and other sulfonamides.","ALL","44 Years",{"count":66,"type":22},270,[68],"PHASE4","Each year, millions of people living at low altitude (\\\u003C 1,000 m) travel to high altitude (≥ 2,500 m) for work, tourism, or sports activities. These individuals are exposed to hypobaric hypoxia, which can trigger acute mountain sickness (AMS)-the most common form of altitude-related illness. Therefore, understanding the physiological responses to hypoxia that allow acclimatization, as well as the pathophysiology of acute mountain sickness, is of primary importance.\n\nThe hematological response to high-altitude exposure initially includes a reduction in plasma volume (PV), leading to an early increase in hemoglobin concentration within the first 24 hours. In contrast, an increase in hemoglobin mass requires several weeks at high altitude. Recent well-controlled physiological studies conducted in hypobaric chambers have demonstrated that this hypoxia-induced PV contraction results from fluid redistribution from the intravascular to the extravascular compartment, rather than from water loss due to increased diuresis.\n\nProphylaxis of AMS is primarily based on the administration of 250 mg\u002Fday of acetazolamide (ACZ), a carbonic anhydrase inhibitor with a mild diuretic effect. Acetazolamide induces metabolic acidosis, which stimulates ventilation and thereby improves oxygenation. The effect of prophylactic ACZ use during high-altitude exposure on PV in lowlanders remains unknown: it is unclear whether ACZ leads to a greater reduction in PV due to its diuretic effect, or to a smaller hypoxia-induced PV contraction as a result of improved oxygenation induced by increased ventilation.",[71,72,73,34,74],"High Altitude Effects","High Altitude Hypoxia","Acute Mountain Sickness (AMS)","Women",[76,77,78,79,80,81],"acetazolamide","plasma volume","acute mountain sickness","high altitude","hypoxia","women","RECRUITING","2025-08-11",{"date":85,"type":48},"2025-08-12",{"date":87,"type":48},"2024-07-15",{"date":89,"type":22},"2025-12-31",{"name":91,"class":55},"Centre d'Expertise sur l'Altitude EXALT",1]